Amarin to Present New REDUCE-IT Data at ESC 2026, Highlighting Long-Term Cardiovascular Benefits — Amarin Corporation plc

Event summary

Amarin will present new analyses from the REDUCE-IT trial and EPA mechanistic data at the European Society of Cardiology (ESC) Congress 2026, August 28-31.
Presentations include studies on treatment adherence, long-term outcomes, lipoprotein(a) [Lp(a)], coagulation biomarkers, and cellular pathways relevant to cardiovascular disease.
Key abstracts focus on sex differences in study discontinuation, effects of icosapent ethyl on coagulation biomarkers, and the impact of EPA on lipoprotein(a) oxidation.
The data builds on the REDUCE-IT trial, which followed 8,179 patients across 11 countries and was completed in 2018.

The big picture

Amarin's presentations at ESC 2026 underscore the ongoing effort to expand the clinical evidence base for VASCEPA/VAZKEPA, particularly in high-risk cardiovascular patients. The focus on long-term outcomes and mechanistic data aligns with broader industry trends toward personalized medicine and biomarker-driven therapies. The scale of the REDUCE-IT trial and its global reach highlight Amarin's commitment to addressing cardiovascular disease, a leading cause of death worldwide.

What we're watching

Clinical Validation: How the new REDUCE-IT data will influence the clinical adoption of VASCEPA/VAZKEPA in high-risk cardiovascular patients.
Regulatory Impact: Whether the mechanistic insights presented at ESC 2026 will support expanded regulatory approvals for Amarin's products.
Market Differentiation: The pace at which Amarin can leverage these findings to differentiate itself in the competitive cardiovascular therapeutics market.